Preview

Purinex Case Solution

Powerful Essays
Open Document
Open Document
1168 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Purinex Case Solution
Executive Summary
Purinex is a drug discovery and development company based in Syracuse, New York. The company sought to commercialize therapeutic compounds based on Purine, which is useful in numerous biochemical processes and its intellectual portfolio of Purinex consists of more than 35 patents, pending and issued in the purine field. The company has a headcount of 14 and maintains a chemistry laboratory a few miles from its main office.
The company’s target is to develop products that act as activators or blockers to specific purine receptors without producing undesirable outcomes. It is on the verge of securing a partnership with a major pharmaceutical company in the next 4-12 months that could seal the fate for it to develop the treatments for the most deadly diseases.
Purinex has plans to take its receptor-selective drugs into clinical trials to address a broad range of potential indications, out of which the most promising were of treatment of Diabetes and Sepsis. As the company has limited funds available and doesn’t have any sales and earnings, Purinex’s CFO, Gilad Harpaz is deciding on two alternatives to keep the company afloat – to obtain financing now or wait until the partnership deal to get through. Brainstorming through pros and cons of each of the two alternatives with factors like current cash availability, clouding uncertainties on Sepsis and Diabetes partnerships, need for raising immediate money, giving up market rights, Harpaz considered following three options in order to maximize firm’s value and reduce financing risks: 1) Venture Capital Round: Secure $10 million in three months amidst various restrictions, 2) Wait six months: $25 million valuation but greater duress if the deal fails, and 3) Angel Round: Lower financing with greater valuation, without any overtly preferential demands.

Key Issues with Purinex
In order to evaluate each of the three options mentioned above, the following key issues need to be

You May Also Find These Documents Helpful

  • Good Essays

    Choose two or three decisions and list the criteria that you will use to make these decisions.…

    • 964 Words
    • 4 Pages
    Good Essays
  • Good Essays

    Merck Case

    • 587 Words
    • 4 Pages

    1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs?…

    • 587 Words
    • 4 Pages
    Good Essays
  • Better Essays

    Merck Kl798 Case

    • 920 Words
    • 4 Pages

    Merck & Company has been presented with an opportunity to invest $30 million for the purchasing rights of an obesity and high cholesterol lowering drug, KL-798 from Kappa Labs. Based on the expected probabilities of success through each product-development phase for this new drug, as well as the costs involved, the net present value of the project is -$1.16 million and is therefore recommended that Merck passes on the investment. Sensitivity analysis also show that adjusting the probabilities of successfully passing each approval process to more realistic expectations has a drastically negative affect on the project NPV.…

    • 920 Words
    • 4 Pages
    Better Essays
  • Satisfactory Essays

    Adneux case study

    • 362 Words
    • 2 Pages

    As an emerging private biotechnology company, Adnexus Therapeutics Inc faces not only the pressure from those established big companies but also obstacles in gathering enough fund. Based on such situation, Dr. John Mendlein strongly recommended that the company find a partner with sufficient monetary and expertise resources. That’s where BMS appeared, showing great interest in ATI’s invention and the cooperation programme. Now the ATI achieved great progress and the future seems promising. BMS becomes more and more serious about purchasing the company’s outright. However, whether to keep the collaborative partnership or to pursuit independent development is hard for ATI to decide. What’s more, the next emphasis on Angiocept or Adnectins reamins unknown.…

    • 362 Words
    • 2 Pages
    Satisfactory Essays
  • Best Essays

    David H. Austin (October 2006). Research and Development in the Pharmaceutical Industry. Received From http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf.…

    • 4398 Words
    • 18 Pages
    Best Essays
  • Satisfactory Essays

    Agency Problems

    • 435 Words
    • 2 Pages

    e. What factors besides the costs and benefits should be considered before the final decision is made?…

    • 435 Words
    • 2 Pages
    Satisfactory Essays
  • Best Essays

    Nucleon was one of over 200 firms founded since the mid-1970s to develop pharmaceutical technologies based on recent technologies in molecular biology and immunology. Not surprisingly, the new field of R&D also attracted the attention of established companies, which meant that competition was intense. Scientists at both established and new companies were racing to…

    • 4924 Words
    • 20 Pages
    Best Essays
  • Good Essays

    c. Identify 3 alternative solutions that you would recommend for the problems identified in the case study. What are the advantages/disadvantages of each of the alternative solutions?…

    • 633 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Biopure Case

    • 1372 Words
    • 6 Pages

    Problem Definition In February 1998 Biopure Corporation faced a difficult decision regarding the launch of its newly developed “blood substitute” products. Biopure had developed “Hemopure”, a blood substitute for humans, and an ancillary product “Oxyglobin” for the veterinary market1. Hemopure was still in the process of gaining Federal Drug Administration (FDA) approval , while Oxyglobin had already been approved and was ready to be launched1. FDA approval was estimated to be two years away2, but this could change as the approval process is inherently complex and uncertain. The main problem Biopure faced was whether to launch Oxyglobin now, or wait until Hemopure was approved and launch both products simultaneously. This was a complex problem as the early launch of Oxyglobin would have both positive and negative repercussions for Biopure. These repercussions needed to be carefully analysed in order to decide what the best course of action is. Another problem was that Biopure had competitors with similar human blood substitute products in the pipeline 3 . Biopure have to consider how to position and price their products in relation to their competitors. An additional problem exists in the pricing of Oxyglobin and Hemopure in order to appeal to their respective markets4. Lastly, Biopure has no current cashflow and therefore needs to be successful with its upcoming IPO in order to raise the requisite cash and solidify its future5. Analysis Human blood is an extremely important commodity as it is used for blood transfusion procedures. However, blood collection is becoming increasingly difficult because donor rates are falling and a lot of collected blood is being discarded due to contamination or expiry6. Biopure identified a need for a “blood substitute” product which would provide the following benefits7: 1) eliminate the need for blood typing and cross matching, 2) free from infectious agents and contamination and 3) increased…

    • 1372 Words
    • 6 Pages
    Good Essays
  • Satisfactory Essays

    soci a301 tma02

    • 407 Words
    • 2 Pages

    First, you will need to carefully identify what the question is asking you to consider. In this…

    • 407 Words
    • 2 Pages
    Satisfactory Essays
  • Good Essays

    Merck Decision Tree

    • 456 Words
    • 2 Pages

    Merck is a global research-driven pharmaceutical company dedicated to putting patients first. Merck's highest priority areas are Alzheimer’s disease, atherosclerosis, cardiovascular disease, diabetes, novel vaccines, obesity, oncology, pain and sleep disorders. In addition, and importantly for licensing, the following other areas remain of high interest for focused investment in new compounds and mechanisms: antibiotics, antifungals, antivirals (HCV and HIV), asthma, COPD, neurodegeneration, ophthalmology, osteoporosis, schizophrenia, and stroke.…

    • 456 Words
    • 2 Pages
    Good Essays
  • Powerful Essays

    Merck Business Analysis

    • 1943 Words
    • 8 Pages

    References: Drug Discovery & Development. (2011). Merck Outlines Long-Term Prospects and Progress on Strategic Plan. Retrieved from http://www.dddmag.com/news-Merck-Outlines-Long-Term-Prospects.aspx…

    • 1943 Words
    • 8 Pages
    Powerful Essays
  • Good Essays

    Pfizer Overview

    • 550 Words
    • 3 Pages

    Pfizer Incorporated is a major pharmaceutical company and is one of the leading in the world for pharmaceutical sales It currently has the largest Research and Development department out of any Bio-medical company in the world. Some of the products that Pfizer produces that readers might be familiar with are: Lipitor (atorvastatin); oral antifungal medication Diflucan (fluconazole), another popular antibiotic Zithromax commonly reffered to as a the “Z” pack (azithromycin), the well-known erectile dysfunction drug Viagra (sildenafil citrate), and the anti inflammatory drug Celebrex (celecoxib)…

    • 550 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Specialty Drugs Analysis

    • 923 Words
    • 4 Pages

    Through my analysis of an Issue Brief from American’s Health Insurance Plan titled Specialty drugs; issues and challenges, I became cognizant of the monopoly system that pharmaceutical companies are presently ascertaining in the United States. These companies are having breakthroughs in the way they handle chronic illnesses. Consequently, numerous of these breakthrough treatments derive from specialty drugs. With complex molecular structures, these specialty drugs are comprised of living organisms. Distinctive delivery and an upsurge in shipping expenses are also necessitated needs demanded by these drugs.…

    • 923 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    Sanofi-Aventis Acquisition

    • 5913 Words
    • 19 Pages

    Bibliography: Cleaves, K., Thayer A., (August 2004). Warning, merge with care: Sanofi-Aventis. Modern Drug Discovery. Retreived on June 6, 2014 from http://pubs.acs.org/subscribe/archive/mdd/v07/i08/pdf/804business2.pdf…

    • 5913 Words
    • 19 Pages
    Powerful Essays